Echo Street Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Echo Street Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,268	Closed	-$368K	–	283
2023 Q3	$368K	Buy	+3,268	New	+$344K	﹤0.01%	336
2023 Q2	–	Sell	-3,073	Closed	-$311K	–	555
2023 Q1	$311K	Buy	3,073 +1,037	+51%	+$108K	﹤0.01%	371
2022 Q4	$243K	Buy	+2,036	New	+$238K	﹤0.01%	438
2022 Q2	–	Sell	-5,536	Closed	-$519K	–	654
2022 Q1	$519K	Sell	5,536 -2,763	-33%	-$234K	﹤0.01%	391
2021 Q4	$707K	Buy	+8,299	New	+$763K	﹤0.01%	336
2021 Q3	–	Sell	-8,724	Closed	-$849K	–	705
2021 Q2	$849K	Buy	+8,724	New	+$836K	0.01%	226

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Echo Street Capital Management's NBIX Position: Q4 2023 in Review

Echo Street Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2023, closing a stake of 3,268 shares — an estimated $368K sold.

Echo Street Capital Management first reported a position in NBIX in Q2 2021 and held it in 6 quarters. The position peaked at $849K in Q2 2021. 555 funds tracked by Wall St. Rank hold NBIX as of Q4 2023.

Echo Street Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2023 after selling out during the quarter.
Echo Street Capital Management sold 3,268 Neurocrine Biosciences shares in Q4 2023, an estimated $368K.
Echo Street Capital Management first reported a position in Neurocrine Biosciences in Q2 2021 and held it in 6 quarters.
Echo Street Capital Management's Neurocrine Biosciences position peaked at $849K in Q2 2021.
555 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2023.

Based on Echo Street Capital Management's 13F filing for Q4 2023, filed 8 Feb 2024.